FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort - Caminiti, Silvia Paola; Ballarini, Tommaso; Sala, Arianna; Cerami, Chiara; Presotto, Luca; Santangelo, Roberto; Fallanca, Federico; Vanoli, Emilia Giovanna; Gianolli, Luigi; Iannaccone, Sandro; Magnani, Giuseppe; Perani, Daniela; et al. (NeuroImage clinical, 2018)
Keywords: AD, Alzheimer's disease; Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - diagnosis; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - psychology; Alzheimer Disease/cerebrospinal fluid/diagnosis/diagnostic imaging/psychology; Alzheimer's disease dementia; aMCI, single-domain amnestic mild cognitive impairment; Amyloid beta-Peptides - cerebrospinal fluid; AUC, area under curve; Biomarkers - cerebrospinal fluid; Brain - diagnostic imaging; bvFTD, behavioral variant of frontotemporal dementia; CBD, corticobasal degeneration; CDR, Clinical Dementia Rating; Clinical setting; Cognitive Dysfunction - cerebrospinal fluid; Cognitive Dysfunction - diagnosis; Cognitive Dysfunction - diagnostic imaging; Cognitive Dysfunction - psychology; Cognitive Dysfunction/cerebrospinal fluid/diagnosis/diagnostic imaging/psychology; CSF, cerebrospinal fluid; Disease Progression; DLB, dementia with Lewy bodies; EANM, European Association of Nuclear Medicine; Erlangen Score; FDG, fluorodeoxyglucose; Female; Fluorodeoxyglucose F18; Frontotemporal dementia; Frontotemporal Dementia - cerebrospinal fluid; Frontotemporal Dementia - diagnosis; Frontotemporal Dementia - diagnostic imaging; Frontotemporal Dementia - psychology; Frontotemporal Dementia/cerebrospinal fluid/diagnosis/diagnostic imaging/psychology; FTD, frontotemporal dementia; Human health sciences; Humans; LR+, positive likelihood ratio; LR-, negative likelihood ratio; Male; MCI, mild cognitive impairment; md aMCI, multi-domain amnestic mild cognitive impairment; md naMCI, multi-domain non-amnestic mild cognitive impairment; Middle Aged; naMCI, single-domain non-amnestic mild cognitive impairment; Neuropsychological Tests; p-tau, phosphorylated tau; PET, positron emission tomography; Phosphorylation; Positron-Emission Tomography; Prognosis; PSP, progressive supranuclear palsy; Radiologie, médecine & imagerie nucléaire; Radiology; Radiology, nuclear medicine & imaging; Regular; Sciences de la santé humaine; Sensitivity and Specificity; t-tau, total tau; tau Proteins - cerebrospinal fluid; Prognosis; CBD; LR; Erlangen Score; md aMCI; FDG; p-tau; AUC; CDR; CSF; naMCI; aMCI; AD; Clinical setting; PSP; md naMCI; MCI; FTD; t-tau; bvFTD; DLB; EANM; Alzheimer's disease dementia; Frontotemporal dementia; PET; dementia with Lewy bodies; frontotemporal dementia; Clinical Dementia Rating; behavioral variant of frontotemporal dementia; European Association of Nuclear Medicine; phosphorylated tau; area under curve; multi-domain amnestic mild cognitive impairment; single-domain non-amnestic mild cognitive impairment; Alzheimer's disease; positive likelihood ratio; corticobasal degeneration